Stockscreener 앱 받기
62.93
9.02%
-6.24
시장 영업 전:
63.36
0.43
+0.68%
Boston Scientific Corp 주식(BSX)의 최신 뉴스
Boston Scientific Corporation $BSX Shares Purchased by Brookstone Capital Management - MarketBeat
Allspring Global Investments Holdings LLC Raises Position in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific study backs use of intravascular ultrasound in PCI - MassDevice
Time To Buy The Dip In Boston Scientific Stock? - Trefis
Is 18.1% Fall In Boston Scientific (BSX) Stock A Buying Opportunity? - Trefis
Boston Scientific (BSX) Faces FTC Second Request in Merger Revie - GuruFocus
Boston Scientific's (BSX) Trial Results Fall Short of Expectatio - GuruFocus
Boston Scientific (BSX) Gains Confidence with CHAMPION-AF Data - GuruFocus
Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Results - The Motley Fool
Boston Scientific (BSX) Downgraded by Raymond James: Target Pric - GuruFocus
Needham Reiterates Buy Rating for BSX with Stable Price Target | - GuruFocus
FDA Clears Boston Scientific's (BSX) Asurys Fluid Management Sys - GuruFocus
Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Results - The Motley Fool
Boston Scientific drops on data for Watchman device for stroke reduction - Seeking Alpha
Boston Scientific Options Spot-On: On March 30th, 83,828 Contracts Were Traded, With 408.25K Open Interest - Moomoo
Boston Scientific Corp Stock (BSX) Closed Down by 9.06% on Mar 30: Facts Behind the Movement - TradingKey
Boston Scientific Just Took A 9% Header. Why Analysts Are Still Bullish. - Investor's Business Daily
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION - GlobeNewswire
Boston Scientific (BSX) Stock Trades Down, Here Is Why - stockstory.org
Boston Scientific drops 9% after mixed trial results - Latest news from Azerbaijan
FTC issued Second Request to Penumbra, Boston Scientific over merger review - TipRanks
Boston Scientific stock tumbles 9% on trial results - Investing.com
Raymond James downgrades Boston Scientific but long-term story remains intact - Investing.com Australia
Boston Scientific Stock Sinks to 2-Year Low. Why Wall Street Is Souring on Trial Data. - Barron's
Boston Scientific Has Fallen 36% From Its High. The CHAMPION-AF Data Could Change Everything - TIKR.com
Deadline Alert: Boston Scientific Corporation (BSX) - GlobeNewswire
Boston Scientific (NYSE:BSX) Earns Outperform Rating from Royal Bank Of Canada - MarketBeat
Boston Scientific Drops Despite Encouraging Trial ReadoutsBoston Scientific (NYSE:BSX) - Benzinga
Boston Sci boasts Champion-AF data but strokes signal a concern - BioWorld MedTech
Boston Scientific posts positive stroke prevention data for Watchman - MedTech Dive
Boston Scientific upside scenario unlikely after data, says Wells Fargo - TipRanks
Boston Scientific (BSX) Stock Drops 8% After Analyst Downgrade on Slowing Growth Concerns - CoinCentral
Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial - Fierce Biotech
Boston Scientific (BSX) slides as 2026 outlook and legal/regulatory overhang weigh on sentiment - quiverquant.com
Boston Scientific wins FDA clearance for fluid management system - MassDevice
Boston Scientific Down Nearly 8%, On Pace For Lowest Close Since January 2024 -- Data Talk - Moomoo
Boston Scientific Corporation Receives FDA Clearance for the Asurys Fluid Management System - marketscreener.com
RBC reiterates Boston Scientific stock rating on trial results - Investing.com
Truist reiterates Buy on Boston Scientific stock after CHAMPION-AF data - Investing.com
Boston Scientific (NYSE:BSX) Hits New 52-Week Low Following Analyst Downgrade - MarketBeat
Boston Scientific stock hits 52-week low at 64.2 USD - Investing.com
Why Boston Scientific Stock Is Sinking Despite Wins - TipRanks
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $90 to $124 - Moomoo
Stifel reiterates Boston Scientific stock rating after trial data - Investing.com
Boston Scientific EKOS System Proven Superior to Standard Care in Treating Acute Pulmonary Embolism, HI-PEITHO Trial Shows - Minichart
Boston Scientific announces conference call discussing first quarter 2026 results - Finviz
Boston Scientific wins FDA clearance for urologic irrigation system By Investing.com - Investing.com India
Boston Scientific wins FDA clearance for urologic irrigation system - Investing.com
Boston Scientific announces FDA clearance for Asurys Fluid Management System - TipRanks
Boston Scientific's Q1 2026 Earnings: What to Expect - Barchart.com
Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System - PR Newswire
Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS - TipRanks
INVESTOR ALERT: Boston Scientific Corporation (BSX) - GlobeNewswire
Jefferies Adjusts Price Target on Boston Scientific to $110 From $120, Maintains Buy Rating - Moomoo
Boston Scientific downgraded to Outperform from Strong Buy at Raymond James - TipRanks
Raymond James downgrades Boston Scientific stock rating on growth concerns - Investing.com
Needham Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth - TipRanks
Why Boston Scientific's big dip could be a bigger opportunity - MSN
Boston Scientific Corporation (BSX) Presents at American College of Cardiology 75th Annual Scientific Session and ExpoSlideshow (NYSE:BSX) 2026-03-29 - Seeking Alpha
Boston Scientific reports positive findings for Ekos endovascular system in pulmonary embolism - MassDevice
Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm - The Malone Telegram
BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - PR Newswire
Data supports Boston Scientific Watchman FLX in stroke reduction - MassDevice
Boston Scientific at American College of Cardiology: Clinical Trials Drive Growth - Investing.com
Boston Scientific Unveils “Practice-Transforming” Trial Data for PE and AF at ACC Conference Call - MarketBeat
List of 57 Acquisitions by Boston Scientific (Mar 2026) - Tracxn
Key facts: Boston Scientific CHAMPION‑AF and HI‑PEITHO Met Endpoints - TradingView
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism - www.bostonscientific.com
CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints - PR Newswire
25,000 Shares in Boston Scientific Corporation $BSX Bought by Waycross Partners LLC - MarketBeat
Boston Scientific Corp (NYSE:BSX) Presents a Compelling Mix of Strong Fundamentals and Technical Breakout Potential - ChartMill
Generate Investment Management Ltd Sells 46,161 Shares of Boston Scientific Corporation $BSX - MarketBeat
1.61%
0.20%
자본화:
|
볼륨(24시간):